chufangao/CTO huggingface dataset:
Clinical trial NCT04000529: Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Official title: A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 122.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-30
Primary completion date: 2024-01-15
Completion date: 2024-01-15
Plan to share individual participant data: NO
Clinical trial NCT03997448: Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Official title: Phase II Study of the Combination of Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Sponsor: Big Ten Cancer Research Consortium (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Funder decision
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-26
Primary completion date: 2020-01-30
Completion date: 2020-01-30
Clinical trial NCT01682083: Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
Official title: COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection
Acronym: COMBI-AD
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 870.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-01-08
Primary completion date: 2017-06-30
Completion date: 2023-07-31
Baseline population: The Intent-to-Treat Population (ITT) consisted of all randomized patients whether or not randomized treatment was administered.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04663126: Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma
Official title: Pilot Study to Test the Feasibility of IV Injected Tc-99m-tilmanocept for Imaging of M2-like Tumour Associated Macrophages in Metastatic Melanoma
Acronym: Tilmanocept
Sponsor: University of Lausanne Hospitals (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: after inclusion of 5 patients, tracer had low uptake (kidney/liver)
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-01
Primary completion date: 2023-01-08
Completion date: 2023-06-19
Plan to share individual participant data: NO
Clinical trial NCT04033562: The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis
Official title: The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis
Sponsor: WellSpan Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: limited enrollment and unable to enroll subjects to reach statistical significance
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-15
Primary completion date: 2021-05-17
Completion date: 2021-05-17
Clinical trial NCT03862248: Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
Official title: Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
Acronym: TriDoRe
Sponsor: Institute of Tropical Medicine, Belgium (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Feasibility of the clinical trial could not be confirmed at the different sites.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-09-30
Primary completion date: 2022-10-01
Completion date: 2022-10-01
Plan to share individual participant data: NO
Clinical trial NCT04308681: A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 399.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-07-29
Primary completion date: 2022-08-04
Completion date: 2023-09-22
Clinical trial NCT02656017: Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
Official title: Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
Acronym: TAME
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 97.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-27
Primary completion date: 2020-12-07
Completion date: 2020-12-07
Plan to share individual participant data: NO
Clinical trial NCT02086175: A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
Official title: A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-12-31
Primary completion date: 2019-07-11
Completion date: 2021-02-01
Plan to share individual participant data: YES
IPD sharing description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD time frame: Data can be shared no earlier than 1 year following the date of publication
IPD access criteria: DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
Clinical trial NCT03147196: Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Official title: Neoadjuvant Treatment of Prostate Cancer With Bicalutamide and Raloxifene Prior to Radical Prostatectomy
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: lack of accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-06-27
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Clinical trial NCT03583333: Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)
Official title: A Multi-national Phase 3, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 274.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-18
Primary completion date: 2022-07-12
Completion date: 2022-07-12
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03633396: A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
Official title: A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis
Acronym: POPLAR
Sponsor: AnaptysBio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 59.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-20
Primary completion date: 2021-04-23
Completion date: 2021-04-23
Baseline population: Intent-to-treat analysis set (all randomized participants)
Plan to share individual participant data: NO
Clinical trial NCT05654779: CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of CLL1-/CD33 Targeted LCAR-AMDR Cells Product in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Sponsor: Institute of Hematology & Blood Diseases Hospital, China (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Both the sponsors and collaborator are considering terminating the study
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-12-12
Primary completion date: 2023-09-26
Completion date: 2023-09-26
Plan to share individual participant data: NO
Clinical trial NCT03617172: PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol
Official title: A Randomized, Double-Blind, Placebo-Controlled Trial to Assess The Efficacy and Safety of Misoprostol in The Prevention of Recurrence of Clostridium Difficile Infection in Adults
Acronym: PROCLAIM
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low enrollment
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-26
Primary completion date: 2021-09-22
Completion date: 2021-09-22
Plan to share individual participant data: NO
Clinical trial NCT03977584: Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease
Official title: Tau PET Longitudinal Substudy Associated With: A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-randomized, Placebo-treated Non-carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 114.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-06-10
Primary completion date: 2022-04-19
Completion date: 2022-04-19
Baseline population: Intent-to-Treat population (ITT) population included all randomized participants who received the assigned study treatment
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT04117607: Safety and Pharmacokinetics of Rezafungin
Official title: A Phase 1, Three-Part, Randomized, Double-Blind, Single and Multiple Subcutaneous Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of Rezafungin in Healthy Adult Subjects
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Stopped due to the formation of injection site skin nodules.
Enrollment: 14.0 (ACTUAL)
Number of arms: 12.0
Start date: 2019-12-04
Primary completion date: 2020-05-11
Completion date: 2020-05-11
Baseline population: Number of subjects randomized.
Clinical trial NCT03231475: Phase I Study of SPH1188-11 in NSCLC
Official title: Phase I, Open-label Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of SPH1188-11 Tablets for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
Acronym: SPH1188-11
Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Board decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-21
Primary completion date: 2020-12-31
Completion date: 2022-03-31
Plan to share individual participant data: NO
Clinical trial NCT02356458: Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Official title: Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Sponsor: Swiss Group for Clinical Cancer Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: SAKK Board decision of 14th November 2020 due to financial reasons.
Enrollment: 58.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-08-31
Primary completion date: 2021-03-30
Completion date: 2021-03-30
Plan to share individual participant data: NO
Clinical trial NCT05543356: COVID-19 Fourth Dose Study in Australia
Official title: A Randomised Controlled Trial to Assess the Immunogenicity, Safety and Reactogenicity of a Second Standard Monovalent (Ancestral) or Bivalent Omicron-specific COVID-19 Vaccine Booster Dose (Pfizer-BioNTech or Moderna) in Healthy Adults in Australia.
Sponsor: Murdoch Childrens Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Withdrawal of supply of vaccine from one manufacturer
Enrollment: 0.0 (ACTUAL)
Number of arms: 8.0
Start date: 2022-05-02
Primary completion date: 2022-07-25
Completion date: 2022-11-30
Plan to share individual participant data: YES
IPD sharing description: We will share de-identified data to ethically approved studies in cases where participants have indicated on the consent form that they consent to the use of their data and where consistent with terms of collaboration agreements.
IPD time frame: Individual participant data (IPD) sharing plans in development
IPD access criteria: In development
Clinical trial NCT04867252: Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome
Official title: Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome
Sponsor: Khyber Medical University Peshawar (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 88.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-03
Primary completion date: 2021-08-03
Completion date: 2021-08-03
Plan to share individual participant data: NO
Clinical trial NCT03724149: Transplanting Hepatitis C Lungs Into Negative Lung Recipients
Official title: Open-Labeled Trial Of Direct-acting Antiviral Treatment Of Hepatitis C-Negative Patients Who Receive Lung Transplants From Hepatitis C-Positive Donors
Acronym: SHELTER
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-12
Primary completion date: 2021-12-31
Completion date: 2022-12-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02579096: CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
Official title: CSP #594 - Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
Sponsor: VA Office of Research and Development (FED)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 950.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-06
Primary completion date: 2021-02-01
Completion date: 2021-04-15
Plan to share individual participant data: YES
IPD sharing description: Individual Participant Data will be made available after study closure only to research credentialed Veterans Affairs researchers who submit a valid study question to their IRB of record. A Data Use Agreement will be in effect between the researcher and the coordinating center
IPD time frame: After primary and secondary analyses and subsequent publications
IPD access criteria: Executed data use agreement with CSP Coordinating Center approval
Clinical trial NCT02207231: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
Official title: Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
Acronym: VOYAGE 1
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 837.0 (ACTUAL)
Number of arms: 3.0
Start date: 2014-11-26
Primary completion date: 2015-09-29
Completion date: 2020-06-17
Baseline population: Randomized analysis set included all participants who were randomized at Week 0.
Limitations and caveats: All participants were on guselkumab after Week 48; therefore, there was no concurrent control group within the study after Week 48.
Clinical trial NCT04625114: The Potential of Camostat in COVID-19
Official title: The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden
Acronym: COV-AAT
Sponsor: University Hospital, Ghent (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Interim analyses did not show evidence that camostat mesylate under the present conditions (300 mg three times daily for five or 10 consecutive days, fasted state) was effective as an antiviral drug against early phase SARS-CoV-2 disease.
Enrollment: 108.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-04
Primary completion date: 2022-07-12
Completion date: 2022-07-12
Baseline population: Between Nov2020 and Jun2021, a total of 108 participants were enrolled in the study. 12 subjects did not meet the in- and exclusion criteria and were excluded from randomization. A total of 96 participants received either camostat (N=66) or placebo (N=30). Treatment was interrupted in 4 subjects that had to be hospitalized due to clinical deterioration. Two other subjects chose to withdraw from the study. Analyses were performed on the data of 90 participants who completed treatment.
Plan to share individual participant data: NO
Clinical trial NCT02462538: Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
Official title: A Window of Opportunity Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ineligible for Chemotherapy
Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Due to slow recruitment, recruitment of new patients was stopped, FU was completed for enrolled patients
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-11-03
Primary completion date: 2021-11-03
Completion date: 2021-11-03
Clinical trial NCT02519322: Neoadjuvant and Adjuvant Checkpoint Blockade
Official title: Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 53.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-02-02
Primary completion date: 2023-01-26
Completion date: 2023-01-26
Baseline population: No participants were in the Arm A or Arm B only Arm C
Clinical trial NCT06159062: A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection
Official title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 162 With a Single Ascending Dose in Subjects With Chronic Hepatitis B Virus Infection
Sponsor: Yangshengtang Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Enrollment difficulty
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-06-03
Primary completion date: 2024-07-09
Completion date: 2024-07-09
Plan to share individual participant data: NO
Clinical trial NCT03970109: HLAB-002 of ANS-6637 for Alcohol Use Disorder
Official title: Human Laboratory Study of ANS-6637 for Alcohol Use Disorder
Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated early following enrollment of n=43 due to clinically significant increases in liver enzymes in 3 women following at least 3 weeks of dosing with both doses of ANS-6637.
Enrollment: 43.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-10-08
Primary completion date: 2020-05-22
Completion date: 2020-05-22
Baseline population: Sample sizes are based on the modified intention-to-treat (mITT) analysis set, defined as subjects randomized to participate in the study that took at least one dose of IP and had a non-missing VAS craving primary endpoint.
Limitations and caveats: Early termination leading to small numbers of subjects analyzed.
Plan to share individual participant data: NO
IPD sharing description: The data will be shared under a clinical trials agreement with Amygdala Neurosciences.
Clinical trial NCT03729310: Comparison of Two Steroid Nasal Implants Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis
Official title: Comparison of Two Steroid Nasal Implants Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-31
Primary completion date: 2020-05-26
Completion date: 2020-05-26
Plan to share individual participant data: NO
Clinical trial NCT04050553: A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
Official title: A Randomized, Placebo-Controlled, Crossover Study to Investigate the Effect of Once-Weekly Tirzepatide on the Counter-Regulatory Response to Hypoglycemia in Patients With Type 2 Diabetes Mellitus
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 42.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-24
Primary completion date: 2022-01-25
Completion date: 2022-01-25
Baseline population: All randomized participants.
Plan to share individual participant data: NO